期刊簡介 | |||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Cellular and Molecular Bioengineering LetPub Score 6.3
50 ratings
Rate
Reputation 7.6 Influence 4.7 Speed 9.0 | ||||||||||||||||||||||||||
期刊簡稱 | CELL MOL BIOENG | ||||||||||||||||||||||||||
ISSN | 1865-5025 | ||||||||||||||||||||||||||
E-ISSN | 1865-5033 | ||||||||||||||||||||||||||
h-index | 27 | ||||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||||
自引率 (2023-2024) | 4.30%自引率趨勢 | ||||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||||
官方網站 | https://www.springer.com/12195 | ||||||||||||||||||||||||||
在線稿件提交 | https://www.editorialmanager.com/camb | ||||||||||||||||||||||||||
開放訪問 | No | ||||||||||||||||||||||||||
出版商 | Springer International Publishing | ||||||||||||||||||||||||||
主題領域 | 生物 | ||||||||||||||||||||||||||
出版國/地區 | UNITED STATES | ||||||||||||||||||||||||||
發行頻率 | 四半期刊行 | ||||||||||||||||||||||||||
創刊年 | 2008 | ||||||||||||||||||||||||||
每年文章數 | 27每年文章數趨勢 | ||||||||||||||||||||||||||
黃金OA百分比 | 14.41% | ||||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q3
| ||||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1865-5025%5BISSN%5D | ||||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: >12 Week(s), or Invited contributions | ||||||||||||||||||||||||||
競爭力 * | 來自作者的數據: Easy | ||||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[Cellular and Molecular Bioengineering] 的評論 | 撰寫評論 |
作者: 刘泰维 領域: 工程技术 審稿時間: 4.0 month(s) 結果: 修改後接受 撰寫評論 |
2024-09-11 11:04:54 評論於 This journal is really slow, and both the impact factor and ranking are very low; I really don't know if this journal is recognized by peers.(0) 讚! | 刘泰维 |
作者: 刘泰维 領域: 数学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-05-11 20:20:39 評論於 Why hasn't my submission been reviewed for almost a month?(0) 讚! | 刘泰维 |
作者: Armstrong Chaucer 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-12-05 12:01:50 評論於 The reviewing speed is simply incredible. Submitted on October 3, 2022, it was sent for review the next day. Feedback was received within a week, and after about a month, the response was returned to the reviewers. Acceptance was received about a week later. Thumbs up to this journal for its speed!(0) 讚! | Armstrong Chaucer |
作者: Armstrong Chaucer 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-10-13 14:39:36 評論於 After about 7 days of the review process, it shows "reviews completed", but I haven't received any emails. What does this mean?(0) 讚! | Armstrong Chaucer |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 20:20:43 評論於 The corresponding author of an SCI journal article does not necessarily have to be only one person, and there is no fixed standard for how many there can be. This is because different SCI journals have different policies regarding the number of corresponding authors. For SCI journals that only accept one corresponding author, if the paper lists multiple corresponding authors, the first corresponding author listed will automatically be selected. For SCI journals that allow two corresponding authors, two corresponding authors can be listed. Other requirements follow the same principle. In other words, the number of corresponding authors listed by the authors must comply with the regulations of the target SCI journal. The first author of an SCI paper is the person who has made the greatest contributions to the experiments and writing of the article, and is the person listed first in the author list. However, in collaborative work, it is common to have multiple co-first authors. There is no clear regulation on the number of co-first authors, and it is closely related to the workload, length of the paper, regulations of the publication, and recognition by institutions. Generally, 2-4 co-first authors are most common for an SCI paper(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 14:40:39 評論於 Choose the journal you want to transfer to in the same publishing company, and submit your manuscript according to the submission guidelines of that journal(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 北国博达 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-28 23:36:19 評論於 How many corresponding authors can there be at most? How many first authors can there be at most?(0) 讚! | 北国博达 |
作者: 上清雨真 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-28 19:33:26 評論於 How to transfer between different issues of the same magazine?(0) 讚! | 上清雨真 |
作者: Onora 領域: 生物 審稿時間: 3.0 month(s) 結果: 修改後接受 撰寫評論 |
2018-11-21 14:16:13 評論於 The reviewers are very professional and all the comments I received for my recent submission were constructive and helpful. I plan to submit the manuscript I’m currently drafting to this journal once I finish it. (0) 讚! | Onora |
作者: 风陵妙夏 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-11-21 12:21:55 評論於 Review speed: 6.0 | Submission acceptance rate: 25.0 Sharing experience: Reviewers are still very diligent and careful. I wonder if the acceptance rate will be higher next year(0) 讚! | 风陵妙夏 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us